ATE481405T1 - Thiazolpyrazolopyrimidine als antagonisten des crf1-rezeptors - Google Patents

Thiazolpyrazolopyrimidine als antagonisten des crf1-rezeptors

Info

Publication number: ATE481405T1
Authority: AT; Austria
Prior art keywords: thiazolpyrazolopyrimidines; antagonists; crf1 receptor; crf1; receptor
Prior art date: 2006-09-20

Application number

AT07842582T

Other languages

English (en)

Inventor

Zhaogen Chen

Chafiq Hamdouchi

Erik Hembre

Philip Hipskind

Jason Myers

Takako Takakuwa

James Toth

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-09-20

Filing date

2007-09-17

Publication date

2010-10-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38924802&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE481405(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2007-09-17 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

2010-10-15 Application granted granted Critical

2010-10-15 Publication of ATE481405T1 publication Critical patent/ATE481405T1/de

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Addiction (AREA)
Pain & Pain Management (AREA)
Reproductive Health (AREA)
Psychiatry (AREA)
Endocrinology (AREA)
Gynecology & Obstetrics (AREA)
Pregnancy & Childbirth (AREA)
Physical Education & Sports Medicine (AREA)
Pulmonology (AREA)
Orthopedic Medicine & Surgery (AREA)
Urology & Nephrology (AREA)
Rheumatology (AREA)
Child & Adolescent Psychology (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Anesthesiology (AREA)
Immunology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AT07842582T 2006-09-20 2007-09-17 Thiazolpyrazolopyrimidine als antagonisten des crf1-rezeptors ATE481405T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US82626406P	2006-09-20	2006-09-20
PCT/US2007/078605 WO2008036579A1 (en)	2006-09-20	2007-09-17	Thiazole pyrazolopyrimidines as crf1 receptor antagonists

Publications (1)

Publication Number	Publication Date
ATE481405T1 true ATE481405T1 (de)	2010-10-15

Family

ID=38924802

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT07842582T ATE481405T1 (de)	2006-09-20	2007-09-17	Thiazolpyrazolopyrimidine als antagonisten des crf1-rezeptors

Country Status (33)

Country	Link
US (1)	US8030304B2 (de)
EP (1)	EP2094709B1 (de)
JP (1)	JP5161226B2 (de)
KR (1)	KR101088239B1 (de)
CN (1)	CN101516887B (de)
AR (1)	AR062886A1 (de)
AT (1)	ATE481405T1 (de)
AU (1)	AU2007297421B2 (de)
BR (1)	BRPI0717023B8 (de)
CA (1)	CA2663511C (de)
CL (1)	CL2007002693A1 (de)
CR (1)	CR10682A (de)
CY (1)	CY1110854T1 (de)
DE (1)	DE602007009305D1 (de)
DK (1)	DK2094709T3 (de)
EA (1)	EA015179B1 (de)
ES (1)	ES2350282T3 (de)
HR (1)	HRP20100516T1 (de)
IL (1)	IL197614A (de)
MA (1)	MA30798B1 (de)
MX (1)	MX2009003125A (de)
MY (1)	MY146388A (de)
NO (1)	NO20091489L (de)
NZ (1)	NZ575572A (de)
PE (1)	PE20081377A1 (de)
PL (1)	PL2094709T3 (de)
PT (1)	PT2094709E (de)
RS (1)	RS51545B (de)
SI (1)	SI2094709T1 (de)
TN (1)	TN2009000095A1 (de)
TW (1)	TWI402269B (de)
UA (1)	UA96458C2 (de)
WO (1)	WO2008036579A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2025674A1 (de)	2007-08-15	2009-02-18	sanofi-aventis	Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
AU2009298757B2 (en) *	2008-10-02	2013-08-01	Eli Lilly And Company	Thiazolyl-pyrazolopyrimidine compounds as synthetic intermediates and related synthetic processes
EP2567959B1 (de)	2011-09-12	2014-04-16	Sanofi	6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridin-4-carbonsäureamid-derivate als kinaseinhibitoren
NZ722122A (en) *	2014-01-21	2020-06-26	Neurocrine Biosciences Inc	Crf1 receptor antagonists for the treatment of congenital adrenal hyperplasia
PL236355B1 (pl) *	2015-04-02	2021-01-11	Celon Pharma Spolka Akcyjna	Pochodne 7-(morfolin-4-ylo)pirazolo[1,5-α]pirymidyny jako inhibitory kinazy PI3
WO2018048953A1 (en)	2016-09-07	2018-03-15	The Regents Of The University Of California	Allosteric corticotropin-releasing factor receptor 1 (crfr1) antagonists that decrease p-tau and improve cognition
AU2018317398A1 (en)	2017-08-14	2019-11-21	Spruce Biosciences, Inc.	Corticotropin releasing factor receptor antagonists
AU2018318990B2 (en) *	2017-08-14	2023-01-05	Spruce Biosciences, Inc.	Corticotropin releasing factor receptor antagonists
BR112020024062A2 (pt) *	2018-04-27	2021-02-09	Spruce Biosciences, Inc.	métodos para o tratamento de tumores de restos adrenais de testículo e de ovário
CN109134481B (zh) *	2018-08-07	2021-05-14	中山大学	一种取代吡咯色原酮类化合物或其药学上可接受的盐及其制备方法和应用
TWI714231B (zh) *	2018-09-04	2020-12-21	美商美國禮來大藥廠	2,6-二胺基吡啶化合物
AU2019393256B2 (en)	2018-12-07	2025-07-31	Neurocrine Biosciences, Inc.	CRF1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia
BR112022000956A2 (pt) *	2019-07-19	2022-04-05	Spruce Biosciences Inc	Métodos de tratamento da hiperplasia adrenal congênita
CN118252829A (zh)	2019-09-27	2024-06-28	纽罗克里生物科学有限公司	Crf受体拮抗剂及使用方法
US20230065034A1 (en) *	2019-12-04	2023-03-02	Neurocrine Biosciences, Inc.	Crf receptor antagonists and methods of use
GR1010096B (el) *	2020-07-02	2021-10-08	Uni-Pharma Κλεων Τσετης Φαρμακευτικα Εργαστηρια Αβεε,	Πυραζολο[1,5-a]πυριμιδινες με δραση αναστολης της αυτοταξινης
JP2023537598A (ja) *	2020-08-12	2023-09-04	スプルースバイオサイエンシーズ，インク．	多嚢胞性卵巣症候群を処置するための方法および組成物
US20240024330A1 (en)	2020-08-26	2024-01-25	Neurocrine Biosciences, Inc.	Crf receptor antagonists and methods of use
WO2022197798A1 (en)	2021-03-19	2022-09-22	Crinetics Pharmaceuticals, Inc.	Melanocortin subtype-2 receptor (mc2r) antagonist for the treatment of disease
US11708372B2 (en)	2021-11-19	2023-07-25	Spruce Biosciences, Inc.	Crystalline composition of tildacerfont and methods of use and preparation thereof
JP2024539907A (ja) *	2021-11-19	2024-10-31	スプルースバイオサイエンシーズ，インク．	チルダセルフォントの結晶性組成物ならびにその使用方法および調製方法
WO2023163945A1 (en) *	2022-02-23	2023-08-31	Crinetics Pharmaceuticals, Inc.	Treatment of congenital adrenal hyperplasia and polycystic ovary syndrome
WO2025188842A1 (en) *	2024-03-08	2025-09-12	Spruce Biosciences, Inc.	Amorphous solid dispersion of tildacerfont formulations

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1994013676A1 (en)	1992-12-17	1994-06-23	Pfizer Inc.	Pyrrolopyrimidines as crf antagonists
CZ244598A3 (cs)	1996-02-07	1998-10-14	Janssen Pharmaceutica N.V.	Pyrazolopyrimidiny jako antagonisty CRF receptoru
EA006626B1 (ru) *	1996-07-24	2006-02-24	Дюпон Фармасьютикалз Компани	Азолопиримидины, фармацевтическая композиция и способ лечения
BR9710544A (pt) *	1996-07-24	1999-08-17	Du Pont Pharm Co	M-todo de tratamento composto e composi-Æo farmac-utica
WO1998008847A1 (en)	1996-08-28	1998-03-05	Pfizer Inc.	Substituted 6,5-hetero-bicyclic derivatives
EP1040831A3 (de) *	1999-04-02	2003-05-02	Pfizer Products Inc.	Verwendung von Corticotropin Releasing Factor (CRF) Antagonisten zur Prophylaxe des plötzlichen Todes
AU4203500A (en) *	1999-04-06	2000-10-23	Du Pont Pharmaceuticals Company	Pyrazolopyrimidines as crf antagonists
DE60032249T2 (de) *	1999-09-30	2007-07-19	Neurogen Corp., Branford	Amino-substituierte Pyrazolo-[1,5-a]-1,5-Pyrimidine und Pyrazolo-[1,5-a]-1,3,5-Triazine
KR100875595B1 (ko) *	2001-03-13	2008-12-23	브리스톨-마이어스 스퀴브 파마 컴파니	코르티코트로핀 방출인자 수용체 리간드로서4-(2-부틸아미노)-2,7-디메틸-8-(2-메틸-6-메톡시피리드-3-일) 피라졸로-[1,5-에이]-1,3,5-트리아진, 그의 거울상이성질체 및 약학적으로 허용가능한 염
AR046967A1 (es)	2003-12-22	2006-01-04	Sb Pharmco Inc	Compuesto de pirazol[1,5-a]pirimidina, composicion farmaceutica que lo comprende y su uso para preparar dicha composicion

2007
- 2007-09-17 DE DE602007009305T patent/DE602007009305D1/de active Active
- 2007-09-17 AT AT07842582T patent/ATE481405T1/de active
- 2007-09-17 WO PCT/US2007/078605 patent/WO2008036579A1/en active Application Filing
- 2007-09-17 MX MX2009003125A patent/MX2009003125A/es active IP Right Grant
- 2007-09-17 SI SI200730435T patent/SI2094709T1/sl unknown
- 2007-09-17 BR BRPI0717023A patent/BRPI0717023B8/pt active IP Right Grant
- 2007-09-17 RS RSP-2010/0517A patent/RS51545B/en unknown
- 2007-09-17 NZ NZ575572A patent/NZ575572A/en not_active IP Right Cessation
- 2007-09-17 US US12/377,733 patent/US8030304B2/en active Active
- 2007-09-17 AU AU2007297421A patent/AU2007297421B2/en not_active Ceased
- 2007-09-17 EP EP07842582A patent/EP2094709B1/de active Active
- 2007-09-17 CN CN2007800351453A patent/CN101516887B/zh active Active
- 2007-09-17 PT PT07842582T patent/PT2094709E/pt unknown
- 2007-09-17 UA UAA200902216A patent/UA96458C2/ru unknown
- 2007-09-17 JP JP2009529316A patent/JP5161226B2/ja active Active
- 2007-09-17 EA EA200970303A patent/EA015179B1/ru active IP Right Revival
- 2007-09-17 HR HR20100516T patent/HRP20100516T1/hr unknown
- 2007-09-17 PL PL07842582T patent/PL2094709T3/pl unknown
- 2007-09-17 DK DK07842582.4T patent/DK2094709T3/da active
- 2007-09-17 MY MYPI20091067A patent/MY146388A/en unknown
- 2007-09-17 ES ES07842582T patent/ES2350282T3/es active Active
- 2007-09-17 KR KR1020097005602A patent/KR101088239B1/ko not_active Expired - Fee Related
- 2007-09-17 CA CA2663511A patent/CA2663511C/en active Active
- 2007-09-18 AR ARP070104125A patent/AR062886A1/es active IP Right Grant
- 2007-09-20 CL CL200702693A patent/CL2007002693A1/es unknown
- 2007-09-20 PE PE2007001271A patent/PE20081377A1/es not_active Application Discontinuation
- 2007-09-20 TW TW096135177A patent/TWI402269B/zh not_active IP Right Cessation
2009
- 2009-03-16 IL IL197614A patent/IL197614A/en active IP Right Grant
- 2009-03-19 TN TN2009000095A patent/TN2009000095A1/fr unknown
- 2009-03-20 CR CR10682A patent/CR10682A/es not_active Application Discontinuation
- 2009-04-16 NO NO20091489A patent/NO20091489L/no not_active Application Discontinuation
- 2009-04-16 MA MA31794A patent/MA30798B1/fr unknown
2010
- 2010-10-21 CY CY20101100946T patent/CY1110854T1/el unknown

Also Published As

Publication number	Publication date
KR20090052366A (ko)	2009-05-25
DK2094709T3 (da)	2010-12-06
EA015179B1 (ru)	2011-06-30
BRPI0717023B8 (pt)	2021-05-25
PT2094709E (pt)	2010-10-04
IL197614A0 (en)	2009-12-24
BRPI0717023A2 (pt)	2014-03-11
JP2010504344A (ja)	2010-02-12
KR101088239B1 (ko)	2011-11-30
CN101516887B (zh)	2011-11-02
RS51545B (en)	2011-06-30
CA2663511A1 (en)	2008-03-27
SI2094709T1 (sl)	2011-01-31
HRP20100516T1 (hr)	2010-10-31
JP5161226B2 (ja)	2013-03-13
PE20081377A1 (es)	2008-09-18
MY146388A (en)	2012-08-15
AU2007297421A1 (en)	2008-03-27
HK1132505A1 (en)	2010-02-26
US20100222339A1 (en)	2010-09-02
WO2008036579A1 (en)	2008-03-27
TW200821312A (en)	2008-05-16
NZ575572A (en)	2011-10-28
CR10682A (es)	2009-08-13
UA96458C2 (ru)	2011-11-10
TN2009000095A1 (en)	2010-08-19
EA200970303A1 (ru)	2009-10-30
BRPI0717023B1 (pt)	2019-11-19
DE602007009305D1 (de)	2010-10-28
EP2094709A1 (de)	2009-09-02
CL2007002693A1 (es)	2008-04-18
AU2007297421B2 (en)	2012-03-08
CN101516887A (zh)	2009-08-26
IL197614A (en)	2012-10-31
ES2350282T3 (es)	2011-01-20
CY1110854T1 (el)	2015-06-10
MA30798B1 (fr)	2009-10-01
CA2663511C (en)	2012-12-04
PL2094709T3 (pl)	2011-02-28
US8030304B2 (en)	2011-10-04
MX2009003125A (es)	2009-05-28
TWI402269B (zh)	2013-07-21
EP2094709B1 (de)	2010-09-15
NO20091489L (no)	2009-04-16
AR062886A1 (es)	2008-12-10

Publication	Publication Date	Title
ATE481405T1 (de)	2010-10-15	Thiazolpyrazolopyrimidine als antagonisten des crf1-rezeptors
EP2013169A4 (de)	2010-12-01	Indolamidderivate als antagonisten des ep4-rezeptors
HRP20151108T1 (xx)	2015-11-20	Antagonisti nogo-receptora
EP2150115A4 (de)	2011-08-03	Cyclopropylpyrrolidinorexin-rezeptorantagonisten
ATE496051T1 (de)	2011-02-15	Pyrazolotetrahydropyridinderivate als orexinrezeptorantagonisten
ATE505467T1 (de)	2011-04-15	2-aza-bicycloä3.1.0ühexanderivate als orexin- rezeptorantagonisten
EP2004654A4 (de)	2010-03-24	Kinase-antagonisten
ES2385606T8 (es)	2013-05-14	Arilimidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina
EP2049110A4 (de)	2011-08-10	Verbrückte diazepanorexin-rezeptorantagonisten
BRPI0717937A2 (pt)	2013-12-03	Compostos de pirazona como antagonistas do receptor mineralocorticóide
EP2083861A4 (de)	2010-11-24	Pcsk9-antagonisten
EP2083860A4 (de)	2010-05-26	Pcsk9-antagonisten
ATE421511T1 (de)	2009-02-15	Indol-3-carbonyl-spiro-piperidinderivate als antagonisten des v1a-rezeptors
ATE555111T1 (de)	2012-05-15	Chinuclidinol-derivate als muscarinrezeptor- antagonisten
ATE429428T1 (de)	2009-05-15	Indanderivate als antagonisten des mch-rezeptors
EP1959959A4 (de)	2011-09-21	Morpholin-carboxamid-prokineticin-rezeptor-antagonisten
DK1973886T3 (da)	2013-03-18	Prokineticin-1-receptor-antagonister
DK2081951T3 (da)	2010-08-09	Progesteron-receptorantagonister
DK2009992T3 (da)	2012-08-13	Il-8 receptor-antagonister
ATE485270T1 (de)	2010-11-15	2-phenylindole als antagonisten des prostaglandin-d2-rezeptors
EP2365749A4 (de)	2012-05-30	Chinolon-neuropeptide-s-rezeptorantagonisten
ATE537149T1 (de)	2011-12-15	Sulfonyl-pyrazolinyl-1-carboxamidinderivate als 5-ht6-antagonisten
EP2254413A4 (de)	2011-10-26	Imidazobenzazepin-cgrp-rezeptorantagonisten
BRPI0817835A2 (pt)	2015-03-31	Antagonistas cgrp
ATE533744T1 (de)	2011-12-15	N-benzoypyrrolidin-3-ylamine als histamin-3 antagonisten

Legal Events

Date	Code	Title	Description
2011-04-15	UEP	Publication of translation of european patent specification	Ref document number: 2094709 Country of ref document: EP

Date

Code

Title

Description

2011-04-15

UEP

Publication of translation of european patent specification

Ref document number: 2094709

Country of ref document: EP